Basic Addyi Information

• INN (International Nonproprietary Name): Flibanserin
• Brand Names Available In United States: Addyi — Sprout Pharmaceuticals, Inc.; 100 mg oral tablets in blister packaging
• ATC Code: G02CX02 (Other Gynecologicals; Miscellaneous)
• Forms & Dosages: Tablet, oral — 100 mg strength; Blister packs (usually 30-tablet supply per carton; US, CA)
• Manufacturers In United States: Sprout Pharmaceuticals, Inc. (sole FDA-approved supplier as of 2025)
• Registration Status In United States: FDA Approved August 18, 2015 for acquired, generalized HSDD in premenopausal women; prescription-only
• OTC / Rx Classification: Prescription Only (Rx)

Everyday Use & Best Practices

Morning Vs Evening Dosing

Do you worry about daytime sleepiness or fainting while taking a new medication?

Addyi (flibanserin 100 mg) is prescribed as 100 mg once daily at bedtime to reduce daytime drowsiness and hypotension risk.

Follow the label’s bedtime recommendation exactly.

If you wake during the night and miss a dose, skip it and resume the next evening—do not double up.

Somnolence and dizziness are common, so avoid driving or operating heavy machinery until you know how the medicine affects you.

• Take Addyi at bedtime to minimize daytime drowsiness and hypotension risk.
• Do not double doses if you miss the bedtime tablet.
• Skip the dose if you wake and missed taking it—resume the next night.
• Avoid hazardous activities like driving until you know how flibanserin affects you.

Taking With Or Without Meals

Is there a required meal with Addyi or a strict mealtime rule?

The official regimen centers on bedtime dosing rather than a strict meal rule.

Practical tip: take Addyi as part of your usual bedtime routine to make adherence easier.

If you experience nausea, try taking it with a light snack before bed.

Crucially, never combine your dose with alcohol; alcohol co‑administration is contraindicated.

Avoid taking Addyi with known moderate or strong CYP3A4 inhibitors unless your clinician advises otherwise.

Store tablets at 20–25°C (68–77°F) in the original blister packaging to protect from moisture and heat.

Use a medicine checklist to track nightly doses and alcohol abstinence for the first weeks.

• Set a nightly alarm or checklist entry for "Addyi at bedtime."
• Keep the blister pack in a consistent bedroom spot to aid routine.
• Record any nausea and try a small snack the next night if it occurs.
• Log alcohol exposure immediately and contact your clinician if an error occurs.

Safety Priorities

Who Should Avoid It

Who needs to skip Addyi for safety reasons?

• Severe hepatic impairment: contraindicated due to increased flibanserin exposure.
• Concomitant use with moderate or strong CYP3A4 inhibitors: contraindicated because they raise flibanserin levels and increase hypotension/syncope risk.
• Known hypersensitivity to flibanserin or any tablet excipient.
• Children, postmenopausal women, and elderly patients: not appropriate users—product is approved for premenopausal women with acquired, generalized HSDD.
• Alcohol users: drinking while taking Addyi is contraindicated because of severe hypotension and syncope risk.
• History of hypotension or syncope, or use of multiple CNS depressants: discuss with your clinician before starting.

Activities To Limit

What activities should be limited while you learn how Addyi affects you?

Limit driving and hazardous tasks until you understand side effects like dizziness and sleepiness.

Avoid alcohol at all times while on Addyi because co‑administration is contraindicated.

Be cautious with sedatives, opioids, benzodiazepines, or strong sleep aids because overlap increases drowsiness and fall risk.

Keep a simple activity log for the first 2–4 weeks noting side effects and any near-falls or fainting episodes to discuss at follow-up.

Dosage & Adjustments

General Regimen

The standard dose is 100 mg orally once daily at bedtime using the Addyi 100 mg tablet.

Clinicians should assess efficacy after about 8 weeks; if there is no meaningful benefit, discontinuation is advised.

For a missed dose, skip it and take the next scheduled bedtime dose—do not double the next evening.

Overdose requires immediate medical attention; expected symptoms include severe low blood pressure, pronounced drowsiness, and risk of syncope.

Supportive care is recommended in overdose situations.

Special Cases

Which patients need dose changes or special caution?

User Testimonials

Positive Reports

What do some women say after trying Addyi for HSDD?

Many premenopausal women report increased sexual desire and improved intimate satisfaction after starting Addyi.

Some users describe better relationship communication after the medication reduced anxiety around desire differences.

Positive stories often mention that benefits emerge within weeks but recommend giving the full 8‑week trial period before judging efficacy.

Users emphasize that Addyi targets sexual desire rather than physical arousal or lubrication issues.

Common Challenges

What practical downsides do people report when using Addyi?

• Dizziness and sleepiness/somnolence that can affect daytime functioning.
• Nausea, dry mouth, and sometimes insomnia which may complicate adherence.
• Alcohol restrictions and bedtime-only dosing can disrupt social routines and travel plans.
• Variable responses—some women see clear benefit, others see little change and stop at 8 weeks.

Use a simple pros/cons checklist at your consultation to weigh expected benefits versus practical challenges.

Buying Guide

Pharmacy Sources

Where should Addyi be purchased and what should you watch for?

Addyi is prescription-only in jurisdictions where approved and is marketed by Sprout Pharmaceuticals as 100 mg tablets in blister packs (typically a 30-tablet supply).

Only purchase from licensed pharmacies—fraudulent online sellers have offered counterfeit or unauthorized products.

Verify pharmacy licensure and request original blister packaging to confirm authenticity.

In our online pharmacy, addyi is available without a prescription, with discreet delivery to United States in 5-14 days.

Price Comparison

How do prices vary and what should you check?

Prices vary by pharmacy, insurance coverage, and manufacturer savings programs.

Typical packaging is 30 tablets for a 30-day supply; compare retail versus mail-order pricing.

Ask about manufacturer coupons, patient assistance programs, and check your insurer’s formulary for copay details.

What’s Inside & How It Works

Ingredients Overview

What is in each tablet?

The active ingredient is flibanserin (INN) at 100 mg per tablet, sold as Addyi by Sprout Pharmaceuticals in blister packs.

Excipients vary by formulation and are listed on the medication leaflet—review that list if you have known allergies.

No other major global brand variations were reported as of 2025.

Mechanism Basics

How does flibanserin act in the brain to affect desire?

Flibanserin acts centrally to modulate neurotransmitter systems tied to sexual desire.

It influences serotonergic receptors and increases central dopamine and norepinephrine activity while reducing inhibitory serotonin signaling.

This neurochemical shift is thought to improve desire in susceptible premenopausal women with acquired, generalized HSDD.

Note that Addyi treats desire and is not a treatment for physiologic arousal problems like lubrication or erection-related issues.

Use simple diagrams or counseling aids to show the balance between serotonin (inhibitory) and dopamine/norepinephrine (excitatory) for patient education.

Main Indications

Approved Uses

What is Addyi officially approved to treat?

The U.S. Food and Drug Administration approved Addyi on August 18, 2015 for acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.

The recommended dose is 100 mg once daily at bedtime and clinicians should reassess benefit after roughly 8 weeks.

Health Canada has similar approval for the same indication.

Off-Label Uses

Are there reliable off-label uses for Addyi?

There is no robust evidence supporting use in postmenopausal women or men, and off-label prescribing is not generally supported by the clinical data.

Clinicians sometimes consider other approved options for HSDD such as bremelanotide (Vyleesi), which is an on‑demand injectable with a different mechanism.

Off‑label testosterone or compounded hormones are sometimes discussed but lack broad regulatory approval for HSDD and carry different risks.

PDE5 inhibitors like sildenafil are not effective for HSDD and are not approved for this indication.

Interaction Warnings

Food Interactions

Can food or beverages change how Addyi works?

The most important dietary rule is to avoid alcohol while taking Addyi due to a clear contraindication for co‑administration stemming from severe hypotension and syncope risk.

Grapefruit juice can act as a CYP3A4 inhibitor in some people and could raise flibanserin levels; discuss grapefruit avoidance with your clinician.

No broad meal-timing restriction is specified, and bedtime dosing minimizes daytime interaction issues.

Drug Conflicts

Which drugs interact with flibanserin and why?

Avoid moderate or strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, and ritonavir because they raise flibanserin exposure and increase hypotension/syncope risk.

Be cautious with CNS depressants like benzodiazepines, opioids, and strong sedative antihistamines because additive drowsiness can occur.

Always provide a complete list of prescription meds, over-the-counter drugs, and supplements to your prescriber before starting Addyi.

Latest Evidence & Insights

What does the evidence say about Addyi’s effectiveness and safety?

• Addyi is the first FDA-approved oral medication for HSDD in premenopausal women, approved August 18, 2015.
• Clinical trial data showed modest but statistically significant improvements in desire measures for some women; response rates vary.
• Clinicians are advised to judge benefits after an approximate 8-week assessment period and discontinue if no meaningful improvement.
• Postmarketing monitoring has flagged hypersensitivity reports that regulators continue to review.
• As of 2025 Sprout Pharmaceuticals is the sole FDA-approved U.S. supplier and no authorized generics have been released; patents run through May 9, 2028 in primary markets.

For up-to-date meta-analyses or safety alerts, consult peer-reviewed journals and FDA label updates.

Alternative Choices

What other options exist for women with low libido?

Non-pharmacologic treatments are foundational and often recommended alone or alongside medication.

These include sex therapy or counseling, relationship or couples therapy, lifestyle optimization (sleep, exercise, stress reduction), and behavioral interventions.

Pharmacologic alternatives include bremelanotide (Vyleesi), an on‑demand injectable approved for HSDD with a different mechanism.

Off‑label testosterone or compounded hormones are sometimes discussed but are not broadly approved for HSDD and carry additional risks.

PDE5 inhibitors like sildenafil are not effective for desire disorders and are not approved for HSDD in women.

Regulation Snapshot

How has Addyi’s regulatory path shaped its use?

The FDA approved flibanserin (Addyi) on August 18, 2015 for acquired, generalized HSDD in premenopausal women after earlier rejections in 2010 and 2013.

Health Canada has similar approval, while broad EU/EMA authorization was not documented publicly by mid-2025.

Sprout Pharmaceuticals is the sole approved U.S. supplier as of 2025 and Boehringer Ingelheim was the original patent assignee.

Patent protections in key markets extend to May 9, 2028 and no authorized generics were available as of 2025.

Beware online fraudulent generics and always verify pharmacy licensing when purchasing.

FAQ Section

Common Questions

Can I drink alcohol on Addyi?

No—alcohol co-administration is contraindicated because it can cause severe hypotension and syncope.

How long until it works?

Assess effectiveness at about 8 weeks; clinicians advise discontinuing if no benefit is seen by then.

Is Addyi for men or postmenopausal women?

No—Addyi is approved only for premenopausal women with acquired, generalized HSDD.

Are generics available?

No authorized generics were available as of 2025.

Quick Answers Checklist

• Confirm premenopausal status and acquired, generalized HSDD diagnosis.
• Review liver history and check for severe hepatic impairment.
• List all medications and supplements for CYP3A4 inhibitor and CNS depressant risks.
• Avoid alcohol entirely while taking Addyi.
• Take the tablet at bedtime and reassess benefit at 8 weeks.
• Report dizziness, fainting, or allergic reactions immediately.

Guidelines For Proper Use

Starting Plan

What should happen before the first tablet?

Confirm the diagnosis of acquired, generalized HSDD and verify premenopausal status.

Review liver function and current medications for potential CYP3A4 inhibitors or CNS depressants.

Discuss the alcohol abstinence requirement and nocturnal dosing strategy with the patient.

Provide a starter checklist including baseline vitals, current meds, counseling resources, and an 8‑week reassessment plan.

Obtain informed consent covering common side effects (dizziness, somnolence, nausea) and rare risks (hypotension, syncope, hypersensitivity).

Monitoring & Follow-Up

How should patients be followed after starting Addyi?

Schedule a follow-up visit or telehealth check at 4–8 weeks to evaluate efficacy and tolerability.

Advise immediate reporting of fainting, severe hypotension, or allergic reactions.

Store pills at 20–25°C (68–77°F) in original packaging and protect from moisture and excessive heat.

Provide written materials and a simple monitoring log for side effects, alcohol exposures, and missed doses to improve adherence and safety.

• Monitoring Log Template Suggestion: Date, Dose Taken (Y/N), Alcohol Exposure (Y/N), Side Effects Noted, Activity Limitations
• Encourage patients to bring the log to the 4–8 week follow-up visit.

Delivery Across United States